Skip to main content

We recommended Abbott Laboratories (Friday’s close $78.57) on August 26, 2017, ($49.35) and again on September 1, 2018, ($66.85). In our first report we provided targets of $54 and $59 then $70 and $74 in the second report. Abbott reached a high of $74.15 in October 2018 to fulfill all of our targets (A).

Recently, the stock settled in a horizontal trading range mostly between $65 and $74 (dotted lines). The recent rise above ±$75 signalled the resumption of the up-trend (B).

A minor correction may occur toward ±$72, but only a sustained decline below $68-69 would be negative.

Point & Figure measurements provide targets of $84 and $94. Higher targets are visible.

Open this photo in gallery:


Monica Rizk is the senior Technical Analyst and Ron Meisels is the president of Phases & Cycles Inc. ( And he tweets at @Ronsbriefs. They may hold shares in companies profiled.

Chart source:

Report an editorial error

Report a technical issue

Editorial code of conduct

Tickers mentioned in this story

Study and track financial data on any traded entity: click to open the full quote page. Data updated as of 28/05/24 8:49am EDT.

SymbolName% changeLast
Abbott Laboratories

Follow related authors and topics

Authors and topics you follow will be added to your personal news feed in Following.

Interact with The Globe